PQQ for cognitive and negative symptoms in schizophrenia
Part of Brain & nervous system, Mental health clinical trials.
This trial tests if a supplement called PQQ can help with cognitive problems and negative symptoms (like lack of motivation) in people with schizophrenia. It may offer a new way to support current treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old.
- You have been diagnosed with schizophrenia for at least 2 years.
- Your symptoms are active, with a certain level of severity on a symptom scale.
- You have been on a stable antipsychotic medication for at least 6 weeks.
- You are not taking antioxidants, anti-inflammatory drugs, certain other medications, or supplements like PQQ.
- You are not pregnant, breastfeeding, or have major medical conditions like liver or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medication called QLM1016 for people with schizophrenia. It aims to see if the drug helps reduce symptoms like delusions, hallucinations, and disorganized thinking.
This trial tests if berberine, a natural supplement, can help reduce negative symptoms like lack of motivation or social withdrawal in people with schizophrenia. It may work by affecting the brain and body.
This Phase 2 trial tests whether a “synbiotic” supplement (a mix of probiotics and prebiotics) can reduce symptoms of schizophrenia or schizoaffective disorder. It may help by targeting gut-related immune and inflammation pathways that could affect brain symptoms.
This study tests whether a medication that boosts brain NMDA receptors can improve negative symptoms in schizophrenia, and looks at differences between men and women. It is for people with stable schizophrenia who still have mostly flat mood or low motivation.
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.